Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

Moderna(MRNA) announced positive results from the pivotal phase III NextCOVE study evaluating mRNA1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older. Image Source: Zacks Investment Research The study achieved its primary efficacy endpoint, demonstrating the non-inferior vaccine efficacy of mRNA1283 against COVID-19 when compared to mRNA-1273.222, Moderna's previously approved bivalent Omicron BA.4/BA.5-targeting COVID-19 vaccine. A higher efficacy was also ...